Skip to main content

Oncology Strategic Sites

  • 8 Oncology Sites
  • 250 + Medical Oncologists
  • 75,000 yearly average for new patients, representing all tumor types
  • 3,000 patients on average enrolled on clinical trials

Sarah Cannon provides the following centralized services to these sites:

  • Study Activation - Sarah Cannon Study Activation department communicates with industry sponsors and CRO’s on behalf of strategic sites. This department centrally coordinates and project manages all study start-up activities from the initial Confidential Disclosure Agreement (CDA) and feasibility completion all the way to SIV and site activation.
  • Contract and Financial – Negotiation and execution of protocol-specific budgets and contracts; invoice sponsor organizations; payment distribution to sites
  • Clinical Operations Support– Provide planning, implementation and support to site through Sarah Cannon leadership team
  • Regulatory Affairs & Safety – Sarah Cannon centrally processes all initial regulatory documents for all Start-Up activities and many of the Maintenance documents for Strategic Sites.  In addition to Regulatory services, Sarah Cannon also provides a central Safety processing group that works directly with Sponsors for timely processing of all IND Safety Reports as well as uploading these reports into a central database for PI review and acknowledgement.
  • Quality Assurance – Sarah Cannon offers a comprehensive quality plan for each investigative site. The quality plan encompasses routine periodic auditing, as well as trending and ensuring resolution of audit observations.  In addition to auditing services, quality team members partner with the sites to support SOP creation, revision and review cycles.  The quality team members provide assistance to the sites with preparation and hosting of external audits / inspections, and consult on issues that arise during the course of a study.
  • Education – Sarah Cannon provides the investigative sites with access to TransCelerate approved GCP training as well as comprehensive curriculum for educational opportunities in both general research and therapeutic areas.

Tennessee Oncology – Nashville,TN

  • Located in middle Tennessee with 25 practice locations
  • Clinical research is conducted at 14 locations which are staffed with oncology research nurses.
  • 50 community-based Medical Oncologists
  • 13,000 new patients each year, representing all tumor types
  • This practice has capabilities and experience in conducting clinical trials in phases I-IV.
  • On average, 1,250 patients are enrolled annually.
  • Sponsor monitoring is conducted out of one central office (250 25th Avenue North, Suite 310, Nashville, TN). Original charts and CRF’s are couriered to the central location for the monitoring.
  • Site has centralized pharmacy for drug shipment, staffed by a dedicated research pharmacist. Drug is then transported to the other clinic locations once a patient has been identified, screened, and is ready to enroll.

Florida Cancer Specialists

(FCS-South) – Fort Myers, FL- (FCS-North) – St. Petersburg, FL - (FCS-East) – West Palm Beach, FL - (FCS PAN) - Tallahassee

  • Located various regions across Florida and serves patients north to Gainesville, on the Gulf Coast from Tampa to Naples, and east through Ormond Beach area with 50 practice locations.
  • Clinical research is conducted at 35 locations with a highly-skilled research staff of oncology research nurses and staff.
  • 150 community-based Medical Oncologists and 119 nurse practitioners.
  • 35,000 new patients each year, representing all tumor types
  • This practice has capabilities and experience in conducting clinical trials in phases I-IV.
  • On average, 500 patients are enrolled annually.
  • Sponsor monitoring is conducted at centralized monitoring locations per region. EMR is used for protocol orders and source documentation. Electronic medical records are accessed at the central location for monitoring.
  • Site has centralized pharmacy at each region for drug shipment. Drug is then transported to the other clinic locations once a patient has been identified, screened, and is ready to enroll.

Tennessee Oncology Chattanooga (TO-Chatt)– Chattanooga, TN

  • Located in Chattanooga, TN with 3 practice locations
  • Clinical research is conducted in 2 locations, all of which are staffed with oncology research nurses.
  • 11 community-based Medical Oncologists
  • 4,000 new patients each year, representing all tumor types
  • This practice has capabilities and experience in conducting phase II, III, and IV clinical trials.
  • On average, 80 patients are enrolled annually. 
  • Sponsor monitoring is conducted out of one central office (605 Glenwood Drive, Suite 200 Chattanooga, TN 37404). Original charts and CRF’s are couriered to the central office for review.
  • Site has centralized pharmacy for drug shipment. Drug is then transported to the other clinic locations once a patient has been identified, screened, and is ready to enroll.

Center for Cancer and Blood Disorders Fort Worth (FTW) – Fort Worth, TX

  • Located in Fort Worth, TX with 11 practice locations that allow for outreach to West Texas populations
  • Clinical research is conducted in 3 locations which are staffed with oncology research coordinaors
  • 12 community-based Hematologists and Medical Oncologists
  • 5,700 new patients each year, representing all tumor types
  • This practice has capabilities and experience in conducting phase II, III, and IV clinical trials.
  • On average, 50 patients are enrolled annually
  • Sponsor monitoring is centralized at the Main Research Office. Electronic medical records are accessed at the central location for monitoring.
  • Centralized pharmacy for drug shipment. Drug is then transported to the other clinic locations once a patient has been identified, screened, and is ready to enroll.
  • Certified as one of only 23 oncology practices in the nation meeting the rigorous quality of care standards of the Quality Oncology Practice Initiative (QOPI) Certification Program, a new program offered as an affiliate of the American Society of Clinical Oncology (ASCO).

HCA Midwest Health, Kansas City, MO

  • Located in Kansas City.
  • Clinical research initiated at Menorah Medical Center Research Medical Center and Centerpoint Medical Center at HCA Midwest Health, a partner in the Sarah Cannon Cancer Network.
  • The research program is supported and complemented by the health system’s seven hospitals and cancer care outreach sites located in communities throughout metropolitan Kansas City and the surrounding area.
  • The research program has capabilities and experience in conducting clinical trials for both hematology and solid tumor.
  • Site investigators include 13 community-based medical oncologists, 1 hematologist, 3 gyn oncologists and 1 neuro oncologist.
  • Sponsor monitoring is conducted out of one central administrative office. Original charts and regulatory documents are provided at the central location for monitoring. 
  • Site has centralized pharmacy for investigational drug shipment. Investigational drug is then transported to the other clinic locations once a patient has been identified, screened and ready to enroll.